Aktuellt
SENASTE
We raise our 2024 and 2025 sales by 6% and 3% but leave our 2026 estimates largely unchanged. Our revisions are driven by higher Zimmer Biomet contribution near term than we had previously assumed. We like that current partnerships are on track and that the Wound Management segment is growing. It is also good news that opex fell to enable positive EBITDA. All in all, we argue that Q2 was a step in the right direction for Bactiguard.
LÄS MER
